Veliflapon
Veliflapon结构式
|
常用名 | Veliflapon | 英文名 | BAY-X 1005 |
|---|---|---|---|---|
| CAS号 | 128253-31-6 | 分子量 | 361.43400 | |
| 密度 | 1.242g/cm3 | 沸点 | 555.4ºC at 760mmHg | |
| 分子式 | C23H23NO3 | 熔点 | N/A | |
| MSDS | 中文版 美版 | 闪点 | 289.7ºC | |
| 符号 |
GHS07 |
信号词 | Warning |
|
Leukotriene modifiers in the treatment of asthma. Look promising across the board of asthma severity.
BMJ 316(7140) , 1257-8, (1998)
|
|
|
BAY x 1005 attenuates atherosclerosis in apoE/LDLR - double knockout mice.
J. Physiol. Pharmacol. 58(3) , 583-8, (2007) Recently, we have shown that MK-886 - an inhibitor of five lipoxygenase activating protein (FLAP) inhibits atherosclerosis in apolipoprotein E / LDL receptor - double knockout mice. We, therefore, wanted to find out if other FLAP inhibitor - BAYx1005 given at... |
|
|
Inhibition of 5-LO activating protein (FLAP) activity decreases proteinuria in streptozotocin (STZ)-induced diabetic rats.
Adv. Exp. Med. Biol. 507 , 79-83, (2002)
|
|
|
Pharmacology of the 5-lipoxygenase inhibitors BAY Y 1015 and BAY X 1005 in the horse.
J. Vet. Pharmacol. Ther. 20(4) , 296-307, (1997) Calcium ionophore A23187 induced time and concentration dependent production of immunoreactive leukotriene (LT) B4 by equine heparinized whole blood in vitro. Time dependent production of immunoreactive LTB4 by equine neutrophils and immunoreactive LTC4 by eq... |
|
|
Potential anti-inflammatory effects of 5-lipoxygenase inhibition--exemplified by the leukotriene synthesis inhibitor BAY X 1005.
J. Physiol. Pharmacol. 48(4) , 529-36, (1997) Leukotrienes have been identified in various pathophysiologies. The leukotrienes LTB4 and LTC4 are assigned to inflammation. 5-lipoxygenase inhibitors which inhibit the synthesis of LTA4 being the precursor of both LTB4 and LTC4 appear to have only a limited ... |
|
|
Ineffective elimination of Leishmania major by inflammatory (MRP14-positive) subtype of monocytic cells.
Immunobiology 202(5) , 442-59, (2000) Myeloid-related protein (MRP) 14, an intracellular protein involved in calcium-dependent activation of myeloid cells, presents a differentiation marker for a subtype of macrophages. In experimental leishmaniasis, BALB/c mice succumb to visceral dissemination ... |
|
|
Antiedematous effects of combination therapies with the leukotriene synthesis inhibitor BAY X 1005 in the archidonic acid-induced mouse ear inflammation test.
Prostaglandins Leukot. Essent. Fatty Acids 56(4) , 301-6, (1997) The leukotriene synthesis inhibitor (LSI) BAY X 1005 was tested in the arachidonic acid (AA)-induced mouse ear inflammation test (AA-MEIT) alone and in combination with other representative anti-inflammatory compounds for antiedematous effects. When BAY X 100... |
|
|
MUC5AC mucin release from human airways in vitro: effects of indomethacin and Bay X1005.
Mediators Inflamm. 10(1) , 33-6, (2001) Increased secretion of mucus is a hallmark of many respiratory diseases and contributes significantly to the airflow limitation experienced by many patients. While the current pharmacological approach to reducing mucus and sputum production in patients is lim... |
|
|
Favorable combination effects of the leukotriene synthesis inhibitor BAY X 1005 and dexamethasone on edema formation in the arachidonic acid-induced mouse ear inflammation test
Prostaglandins Leukot. Essent. Fatty Acids 60(1) , 5-11, (1999) The effects of a combination of the leukotriene synthesis inhibitor (LSI) BAY X 1005 with the glucocorticosteroid dexamethasone were studied in the arachidonic acid (AA)-induced mouse ear inflammation test (AA-MEIT). We have determined the dose-dependent effe... |
|
|
Inhibition of allergen-induced airway obstruction and leukotriene generation in atopic asthmatic subjects by the leukotriene biosynthesis inhibitor BAYx 1005.
Thorax 52(4) , 342-7, (1997) Leukotriene receptor antagonists significantly blunt allergen-induced bronchoconstriction in asthmatic subjects. Inhibitors of leukotriene synthesis should theoretically provide similar protection, but conflicting results have been obtained when synthesis inh... |